[go: up one dir, main page]

WO2019098969A3 - Dry powder compositions for inhalation - Google Patents

Dry powder compositions for inhalation Download PDF

Info

Publication number
WO2019098969A3
WO2019098969A3 PCT/TR2018/050437 TR2018050437W WO2019098969A3 WO 2019098969 A3 WO2019098969 A3 WO 2019098969A3 TR 2018050437 W TR2018050437 W TR 2018050437W WO 2019098969 A3 WO2019098969 A3 WO 2019098969A3
Authority
WO
WIPO (PCT)
Prior art keywords
dry powder
inhalation
powder compositions
long
acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2018/050437
Other languages
French (fr)
Other versions
WO2019098969A2 (en
Inventor
Ali TÜRKYILMAZ
Devrim Celik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arven Ilac Sanayi ve Ticaret AS
Original Assignee
Arven Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi ve Ticaret AS filed Critical Arven Ilac Sanayi ve Ticaret AS
Priority to EP18869456.6A priority Critical patent/EP3672574A2/en
Publication of WO2019098969A2 publication Critical patent/WO2019098969A2/en
Publication of WO2019098969A3 publication Critical patent/WO2019098969A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to dry powder pharmaceutical compositions comprising a corticosteroid, a long-acting beta2-adrenergic agonist and a long-acting muscarinic antagonist and their administration by means of inhalers in the treatment of chronic obstructive pulmonary disease (CORD), asthma and other obstructive airway diseases.
PCT/TR2018/050437 2017-08-21 2018-08-17 Dry powder compositions for inhalation Ceased WO2019098969A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18869456.6A EP3672574A2 (en) 2017-08-21 2018-08-17 Dry powder compositions for inhalation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/12424A TR201712424A2 (en) 2017-08-21 2017-08-21 DRY POWDER INHALATION COMPOSITIONS
TR2017/12424 2017-08-21

Publications (2)

Publication Number Publication Date
WO2019098969A2 WO2019098969A2 (en) 2019-05-23
WO2019098969A3 true WO2019098969A3 (en) 2019-08-08

Family

ID=66218398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050437 Ceased WO2019098969A2 (en) 2017-08-21 2018-08-17 Dry powder compositions for inhalation

Country Status (3)

Country Link
EP (1) EP3672574A2 (en)
TR (1) TR201712424A2 (en)
WO (1) WO2019098969A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022045995A1 (en) * 2020-08-28 2022-03-03 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2011093819A2 (en) * 2010-01-28 2011-08-04 Mahmut Bilgic New combination comprising tiotropium
WO2011093817A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising tiotropium, formoterol and budesonide
WO2012049444A1 (en) * 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
WO2012168161A1 (en) * 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
WO2013153146A1 (en) * 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
EP2682101A2 (en) * 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Inhalation Compositions Comprising Glucose Anhydrous
EP2682099A1 (en) * 2012-07-05 2014-01-08 Arven Ilac Sanayi Ve Ticaret A.S. Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists
EP2682097A2 (en) * 2012-07-05 2014-01-08 Arven Ilac Sanayi Ve Ticaret A.S. Dry Powder Inhalers Comprising A Carrier Other Than Lactose
EP2682102A2 (en) * 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Inhalation Compositions Comprising Corticosteroid and Sorbitol
EP2682129A2 (en) * 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
WO2015181262A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201590030A1 (en) 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. DRY POWDER INHALERS, CONTAINING CARRIER, EXCELLENT FROM LACTOSE, AND THIRD COMPONENT

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2011093819A2 (en) * 2010-01-28 2011-08-04 Mahmut Bilgic New combination comprising tiotropium
WO2011093817A1 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising tiotropium, formoterol and budesonide
WO2012049444A1 (en) * 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
WO2012168161A1 (en) * 2011-06-08 2012-12-13 Glaxo Group Limited Combination comprising umeclidinium and a corticosteroid
WO2013153146A1 (en) * 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
EP2682101A2 (en) * 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Inhalation Compositions Comprising Glucose Anhydrous
EP2682099A1 (en) * 2012-07-05 2014-01-08 Arven Ilac Sanayi Ve Ticaret A.S. Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists
EP2682097A2 (en) * 2012-07-05 2014-01-08 Arven Ilac Sanayi Ve Ticaret A.S. Dry Powder Inhalers Comprising A Carrier Other Than Lactose
EP2682102A2 (en) * 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Inhalation Compositions Comprising Corticosteroid and Sorbitol
EP2682129A2 (en) * 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous
WO2015181262A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd

Also Published As

Publication number Publication date
TR201712424A2 (en) 2019-03-21
EP3672574A2 (en) 2020-07-01
WO2019098969A2 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
CA2897464C (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
GB201205632D0 (en) Method and apparatus
MY176176A (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
EP2682108A3 (en) Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose
PH12017502087B1 (en) Tiotropium inhalation solution for nebulization
EA201201397A1 (en) INHALER CONTAINING DISTRIBUTED GLISTER PACKING
MY186229A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
WO2014007781A3 (en) Inhalation compositions
EA201201392A1 (en) PUSH-BUTTON DEVICE
SG149876A1 (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
EA201201393A1 (en) INHALER, DEVELOPED FOR DELIVERY OF MEDICINES AS DRY POWDER
WO2015049519A3 (en) Method and apparatus for making compositions for pulmonary administration
UA115989C2 (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
WO2019098969A3 (en) Dry powder compositions for inhalation
MX368036B (en) Inhalable particles comprising tiotropium and indacaterol.
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
EA201201394A1 (en) INHALER FOR DELIVERY OF MEDICINE IN THE FORM OF DRY POWDER

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018869456

Country of ref document: EP

Effective date: 20200323